Partnering with a US-based CDMO can offer many advantages for pharmaceutical companies looking to the US market.

Esperion is to acquire Corstasis Therapeutics to expand its cardiovascular franchise with the addition of Enbumyst, a ...

New drugs and lucrative markets in the US remain crucial to Europe’s pharma sector, as governments approach closer trade with ...

Aspire Biopharma has partnered with Microsize to advance the development of a new sublingual powder formulation of alprazolam.

Kairos Pharma has signed a binding agreement to acquire exclusive worldwide rights to CL-273 from Celyn Therapeutics.

While some chief executives have left for personal reasons, others have been ousted amid poor company performance.

OSE will now pivot to focus on late-stage pipeline development of its cancer vaccine, Tedopi and its anti-inflammatory drug, lusvertikimab.

Both Novo and obesity market rival Eli Lilly have outlaid significant funds to ensure future demand for oral weight loss drugs is met.

US-based biotechnology company Rallybio has entered a definitive agreement to acquire Candid Therapeutics through a merger transaction.

BioMarin Pharmaceutical has received FDA approval for its sBLA for Palynziq’s use in adolescents aged 12 years and above with ...

BioMarin’s Voxzogo (vosoritide) won FDA approval in paediatric achondroplasia in November 2021 and secured a label extension ...

Novo Nordisk and Vivtex are to co-develop next-generation oral biologic therapies to treat obesity, diabetes and related ...